arrow-circle-full-right arrow-circle-full-up arrow-circle-up arrow-down arrow-right calendar calendar-done facebook flickr home linkedin login pin reload search share signin star twitter video video youtube nav star-plus info signout double-arrow arrow-up checked
Healthcare & Life Sciences

FT Dementia Summit 2019

Path to Progress

London |
Speakers include:
Adrian Ivinson

Adrian Ivinson

UK Dementia Research Institute

Jeff Huber

Jeff Huber

Home Instead Senior Care

Catherine Mummery

Catherine Mummery

National Hospital for Neurology and Neurosurgery

Overview

As the global prevalence of dementia expands and new breakthroughs are made, the market for dementia-related products and services is set to enter a new era.

The FT Dementia Summit will explore the latest advances in diagnosis and treatment while addressing the challenges facing those responsible for bringing new ideas to life. What are the treatments of tomorrow? How is the role of carers evolving? What can policymakers do to support progress?

Join us in London on 18 September 2019 for a full day of networking and knowledge-sharing with stakeholders across the dementia landscape including investors, innovators, carers and key opinion leaders.

fallback
fallback Add to my Calendar 09/18/2019 08:00:0009/18/2019 17:30:00trueFT Dementia Summit 2019As the global prevalence of dementia expands and new breakthroughs are made, the market for dementia-related products and services is set to enter a new era.The FT Dementia Summit will explore the latest advances in diagnosis and treatment while addressing the challenges facing those responsible for bringing new ideas to life. What are the treatments of tomorrow? How is the role of carers evolving? What can policymakers do to support progress?Join us in London on 18 September 2019 for a full day of networking and knowledge-sharing with stakeholders across the dementia landscape including investors, innovators, carers and key opinion leaders.FT-Dementia-Summit-20199f1488aa003469bafb4a15168b9c0facMM/DD/YYYY

Speakers (5)

Adrian Ivinson

Adrian Ivinson

Co-Director and COO
UK Dementia Research Institute

Dr Adrian Ivinson completed his undergraduate and graduate training in the UK before moving to the US where for eight years he was part of the Nature Publishing Group, including Editor of Nature Medicine and Publisher of the Nature monthly journals. He joined Harvard Medical School in 2001 as the founding Director of the Harvard NeuroDiscovery Center. After 12 years leading the centre, Dr Ivinson took the position of Director of Translational Research, allowing him to focus on those programmes with a more overt translational emphasis, and transitioned to Brigham and Women’s Hospital. Dr Ivinson moved back to the UK in 2017 to be the Co-Director and Chief Operating Officer of the newly established UK Dementia Research Institute.

Jeff Huber

Jeff Huber

President and Chief Executive Officer
Home Instead Senior Care

Jeff Huber is President and Chief Executive Officer of Home Instead Senior Care, the leading global provider of home care services for older adults. He was named President in 2010 and added the role of Chief Executive Officer in May 2015. In his position, Jeff oversees global operations and directs strategic planning and advocacy initiatives for the franchise network. He joined Home Instead Senior Care in 1998 as a Franchise Development Manager when the organization consisted of 125 franchises. Today, Home Instead Senior Care provide more than 80 million hours care annually through more than 1,100 franchises offices in 13 countries. Jeff currently serves as a Governor for the Global Future Council on Health and Healthcare at the World Economic Forum and frequently represents Home Instead at global events, including the G7 Conference on Alzheimer’s disease in Tokyo. Under Jeff’s leadership, Home Instead is committed to addressing the challenges of the aging global population by promoting consumer choice in care. Jeff has also increased the organisation’s commitment to leadership development and training to empower CAREGivers and families and to advance the organization’s mission: to enhance the lives of aging adults and their families.       

Catherine Mummery

Catherine Mummery

Clinical Director of Neurology
National Hospital for Neurology and Neurosurgery

Cath Mummery is a consultant neurologist with a special interest in cognitive disorders, working at the National Hospital for Neurology and Neurosurgery. She trained at Kings College Hospital and the National Hospital for Neurology and Neurosurgery, gaining a PhD in cognitive neurology at UCL via an MRC fellowship. She leads the clinical cognitive disorders service at NHNN, a national service with particular interest in genetic and atypical dementias and is clinical director in neurology at NHNN. She has an academic role as Head of Novel Therapeutics at the Dementia Research Centre, UCL and has been senior investigator on over 20 drug trials of disease modifying agents, focussing on early phase and secondary prevention trials in sporadic and genetic forms of dementia. She is UK chief investigator for pivotal studies such as DIAN-TU, trialling immunotherapy in presymptomatic individuals at risk of genetic AD, and a first-in-human phase I antisense oligonucleotide study, reducing tau accumulation in AD. She is Deputy Director for the Leonard Wolfson Experimental Neurology Centre at NHNN, a unit dedicated to early phase trials in neurodegeneration. She has a national role as Chair of ABN Services Committee and works to ensure the neurology voice is heard about clinical matters. She also has an active role in the Royal College of Physicians as neuroscience representative. She is passionate about improving access to research for individuals with AD and sits on the steering committee for the Alzheimer’s Research UK Dementia Access Taskforce, which aims to enhance early recognition of disease, improve access to trials and address challenges new treatments in dementia will bring to the clinic.  ​

Howard Gordon

Howard Gordon

3 Nations Dementia Working Group (3NDWG)

Howard Gordon worked in Care Homes then Hospitals for nearly 20 years as an auxiliary nurse including caring for people living with Dementia. At the beginning of 2014, Howard began to notice changes which he put down to turning 50 and it wasn’t until he saw a BBC Panorama programme about Chris Roberts and his family in June 2016, that alarm bells rang, and he went to my GP. Following various tests, in March 2017, at the age of 54, Howard was diagnosed with Alzheimer’s and Frontotemporal Dementia. Since then, Howard has become a member of organisations including the 3 Nations Dementia Working Group, Steering group. the Prime Ministers Champions Group, a board member of Dementia Alliance International advocating for change in Dementia Care, rights, better understanding and an end to stigma.

Alison Murray

Alison Murray

Head of Inspection, London, Adult Social Care Inspection Directorate
Care Quality Commission

Alison Murray is a registered nurse, with many years’ experience in both the NHS and private sector. She has specialist qualifications in the care of older people, and spent a number of years managing large nursing homes. Alison has worked in regulation since 2002. She worked with Bradford University to devise the Short Observational Framework for Inspection (SOFI), and led its implementation within CSCI/CQC. Alison then moved to work with the CQC Provider Relationship team, before returning to frontline operations. Alison is currently Head of Inspection in London and takes the lead for dementia care within the CQC Adult Social Care Directorate.  

fallback

Chaired by (1)

Clive Cookson

Clive Cookson

Science Editor
Financial Times

Clive Cookson is Science Editor at the Financial Times. He joined the newspaper in 1988 as Technology Editor and has also written about the chemical and pharmaceutical industries. Previously, he was the science and medical correspondent for BBC Radio. He also spent four years in Washington DC as American Editor of the Times Higher Education Supplement. He has won several science journalism awards and is an honorary member of the British Science Association and the American Academy of Arts and Sciences. Mr Cookson graduated from Oxford University with a first class honours degree in Chemistry.

Agenda - 18th Sep

  • 8:00am
    Breakfast and Registration
  • 9:00am
    Opening Remarks

    Clive Cookson, Science Editor, Financial Times

  • 9:10am
    The Cost of Dementia

    The increased prevalence of dementia is having a major socio-economic impact. How are the demographics changing? What is the trajectory for healthcare spending on dementia care? What are the trends for investment in dementia research?

  • 9:40am
    Keynote: A Call to Action

    Combating dementia requires investment, innovation and collaboration. Advocacy from influencers is also crucial to progress and this speaker is one of them.

  • 10:10am
    Panel: Building a Movement for Change
    • What are some of the misconceptions about dementia that need to be overcome?
    • Where are dementia charities succeeding and failing?
    • What commitments should governments be making to combat dementia?
    • How can private investment in dementia-related products and services be encouraged?
    • How can a more joined-up approach between stakeholders be achieved?
  • 10:55am
    Morning Refreshments
  • 11:15am
    Business Taking on Dementia

    Businesses are beginning to pay attention to the needs of workers and customers with dementia. What can employers do to help people who are in the early stages of dementia? How are consumer-facing industries like travel, retail and utility supply changing their offerings to accommodate dementia sufferers?

  • 11:45am
    Investing in Advanced Therapies for Dementia

    Gene therapies may herald a new era for the war on cancer, but what is their potential for treatment of Alzheimer’s, Parkinson’s and other forms of dementia? When could we see products on the market? Will treatments be affordable?

  • 12:15pm
    Panel: Dementia R&D Landscape
    • Where is investment in dementia R&D strongest?
    • What are some of the latest advances in dementia diagnosis?
    • What are some of the latest advances in drugs to alleviate symptoms?
    • How are dementia clinical trials evolving?
    • Is immunotherapy the way forward as a cure for dementia?
  • 1:00pm
    Networking Lunch
  • 2:00pm
    View from the Frontline of Dementia Care

    In order to achieve major improvements in dementia care, it is crucial to listen to those nresponsible for its delivery.

  • 2:30pm
    Panel: The Future of Dementia Care
    • Are we seeing a shift in the paradigm for dementia care?
    • What is the potential for digital therapeutics in dementia care?
    • What are some of the growing business opportunities in dementia care?
    • How can employers be more sensitive to needs of people with dementia?
    • How are lawyers and insurers evolving to meet the needs of those with dementia?
  • 3:15pm
    Afternoon Refreshments
  • 3:35pm
    Policy Outlook for Dementia

    The increased prevalence of dementia and advances in dementia care are putting pressure on governments to do more. How are health and social care policies changing? What regulatory reforms are needed? Which countries are leading the way?

  • 4:05pm
    Predictions for 2020 and Beyond

    As the event draws to a close, a panel of experts will discuss highlights of the day and share insights on developments for dementia they expect to see in the coming decade.

  • 4:25pm
    Closing Remarks
  • 4:30pm
    Drinks Reception

Why attend

  • Hear from key opinion leaders at the cutting edge of dementia research
  • Explore new ideas to achieve a more dementia-friendly society
  • Analyse the market for dementia-related products and services
  • Network with the full spectrum of stakeholders across the dementia landscape
fallback

Who attends

  • Pharma-biotech and medical devices companies
  • Commercial dementia care management services 
  • Medicine and academia
  • Government and public services
  • Charities
fallback

Venue

30 Euston Square at the Royal College of General Practitioners
1 Melton Street
London NW1 2FB

United Kingdom

Tel: +44 (0) 20 8453 4610

fallback

Presented by (1)

The Financial Times is one of the world’s leading business news organisations, recognised internationally for its authority, integrity and accuracy. The FT has a record paying readership of one million, three-quarters of which are digital subscriptions. It is part of Nikkei Inc., which provides a broad range of information, news and services for the global business community.

Lead Sponsor (1)

Founded in 1994, the Home Instead Senior Care® franchise network provides personalized care, support and education to enhance the lives of aging adults and their families. Today, the network is the world's leading provider of in-home care services for seniors, with more than 1,200 independently owned and operated franchises that provide more than 80 million hours of care annually across 13 countries on four continents.  Local Home Instead Senior Care offices employ more than 90,000 CAREGivers worldwide who provide basic support services that enable seniors to live safely and comfortably in their own homes for as long as possible. Home Instead Senior Care franchise owners partner with clients and their family members to help meet varied individual needs. Services span the care continuum – from providing personal care to specialized Alzheimer’s care and hospice support. Also available are family caregiver education and support resources.

Visit HomeInstead.com. Connect with us on Facebook and Twitter.

Partner Association (2)

Contact us

Alexsandra Silva
Media Partner and Press Enquiries
Financial Times
Ciaran Larkin
Speaking Opportunities
Financial Times
Joe Hames
Sponsorship Opportunities
Financial Times
FT Live Delegate Services - EMEA
Delegate Booking and Registration Enquiries
Financial Times